Published on 13th August 2013
ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients.
URL: http://www.digitallook.com/dl/news/story/21089768/...